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Abstract 29 
Olive oil (OO) is the primary source of fat in the Mediterranean diet and has been associated 30 
with longevity and a lower incidence of chronic diseases, particularly coronary heart disease. 31 
Cardioprotective effects of OO consumption have been widely related with improved lipoprotein 32 
profile, endothelial function and inflammation, linked to health claims of oleic acid and phenolic 33 
content of OO. With cardiovascular disease being a leading cause of death worldwide, a review 34 
of the potential mechanisms underpinning the impact of OO in the prevention of disease is 35 
warranted. The current body of evidence relies on mechanistic studies involving animal and cell-36 
based models, epidemiological studies of OO intake and risk factor, small and large scale human 37 
interventions, and the emerging use of novel biomarker techniques associated with disease risk.  38 
While model systems are important for mechanistic research nutrition, methodologies and 39 
experimental designs with strong translational value are still lacking. This review critically 40 
appraises the available evidence to date, with particular focus on emerging novel biomarkers for 41 
disease risk assessment. New perspectives on OO research are outlined, especially those with 42 
scope to clarify key mechanisms by which OO consumption exerts health benefits. The use of 43 
urinary proteomic biomarkers, as highly specific disease biomarkers, is highlited towards a 44 
higher translational approach involving olive oil in nutritional recommendations. 45 
 46 
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 59 
1. Relevance of the Mediterranean diet and olive oil to health 60 
The olive tree, Olea europaea L., is one of the oldest agricultural tree crops and provides 61 
diversified products for human consumption such as table olives and olive oil (OO)
(1)
. The 62 
analytical parameters to ascertain OO quality and classify OOs are defined by European Union 63 
(EU) regulations
(2)
. Oils obtained only by mechanical extraction are virgin olive oils (VOOs) and 64 
further quality assessment can lead to a classification as extra virgin olive oil (EVOO)
(3)
.  65 
OO is the primary source of fat in the Mediterranean diet and has been associated with longevity 66 
and a lower incidence of chronic diseases, particularly coronary heart disease (CHD)
(4-7)
. OO 67 
consumption is also associated with decreased rates of cancer, diabetes and neurodegenerative
 
68 
diseases
(8) 
as well as body weight reduction and obesity prevention
(9, 10)
. The epidemiological 69 
evidence underpinning the relevance of the Mediterranean diet to health is strong with over 70 
seventeen studies including 2300 volunteers confirming that a Mediterranean diet decreases 71 
inflammation and improves endothelial function
(11)
, and a meta-analysis of thirty-two cohort 72 
studies (> 800,000 subjects) indicating that there is an inverse correlation between OO intake and 73 
coronary heart disease
(12)
.    74 
 75 
Olive oil bioactive components  76 
The major components of OO are glycerols (saponifiable fraction) which represent more than 77 
98% of of the total oil weight and are mainly triglyceride esters of oleic acid (55 to 83%), 78 
palmitic acid (7.5 to 20%), linoleic acid (3.5 to 21%) and other fatty acids such as stearic acid 79 
(0.5 to 5%)
(13)
. Minor components (the unsaponifiable fraction) include aliphatic and triterpenic 80 
alcohols, sterols, hydrocarbons as squalene, volatile compounds, tocopherols, carotenes, 81 
chlorophyll and phenolic compounds
(13-15)
.  82 
Special attention has been given to the phenolic compounds only found in VOO and EVOO. The 83 
agronomic and technological aspects of OO production have an impact on the concentration of 84 
phenolic compounds, as does the pedoclimatic conditions and agronomic techniques              85 
(e.g.: irrigation)
(4, 14)
. The main classes of phenolic compounds present in VOO are phenolic 86 
acids, phenolic alcohols (hydroxytyrosol and tyrosol), flavonoids, lignans and secoiridoids, 87 
Table 1.  88 
Oleuropein and ligstroside, the most significant secoiridoids in Olea europaea L., are esters of 89 
elenolic acid glucoside with hydroxytyrosol and tyrosol, respectively. During the mechanical 90 
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extraction of the oil, fruit endogenous β-glucosidases(14, 16) are released leading to the secoiridoid 91 
aglycones formation, accounting for more than 50% of the phenolic content of the oil
(17, 18)
. The 92 
most abundant secoiridoids of VOO are the oleuropein and ligstroside aglycons and dialdehydic 93 
forms of deacetoxy of oleuropein and ligstroside aglycons
(14)
 also named oleacein and 94 
oleocanthal, respectively
(19)
.  95 
 96 
Phenolic compounds bioavailability and bioactivity 97 
Once OO has been ingested, it produces a micellar solution composed of a lipid and an aqueous 98 
phase. Chemical hydrolysis of secoiridoids can take place in the acidic medium of the 99 
stomach
(20)
 or in alkaline conditions in the small intestine
(21, 22)
 leading to an increase of free 100 
phenolic alcohols released into the aqueous phase. As a result OO phenolic compounds are 101 
further absorbed in the small intestine
(23)
. Measuring the bioavailability of these compounds in 102 
plasma and urine reveals that OO phenolics undergo a conjugation process of methylation, 103 
glucuronidation and sulfation indicating that there is phase 2 metabolism involved during the 104 
absorption of these compounds
(24-27)
. The between-subjects variability in human absorption and 105 
metabolism of OO phenolics may explain differences in proportion of methyl, glucuronide and 106 
sulfate conjugates reported
(28-30)
. 107 
 108 
Bioavailability of OO phenolic compounds differs according to the intake matrix. OO as the 109 
intake vehicle promotes absorption of hydroxytyrosol: the corresponding bioavailability of 110 
hydroxytyrosol in rats for aqueous and OO solutions were reported as 75 and 99%
(31)
, 111 
respectively. When a supplement containing hydroxytyrosol as a single oral dose (2.5 mg/kg) 112 
was fed to humans, the bioavailability was below 10%
(32)
, while previous studies showed higher 113 
bioavailability for hydroxytyrosol supplementation in lipid vehicles
(33)
. The addition of 114 
hydroxytyrosol to low fat yogurt and administered to humans was also associated with a lower 115 
excretion of hydroxytyrosol when compared with OO
(33)
. As OO phenolic compounds are mainly 116 
absorbed in the small intestine
(23)
 the increase of hydroxytyrosol bioavailability, in OO, might be 117 
related to the rate of gastric emptying
(32)
 and slow release of hydroxytyrosol from the oil 118 
matrix
(26, 32)
. The presence of other antioxidants in OO might prevent breakdown of 119 
hydroxytyrosol before absorption in the gastrointestinal tract
(31)
.   120 
 121 
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Secoiridoids that are not absorbed in the small intestine are degraded by the colonic microbiota 122 
with oleuropein producing hydroxytyrosol as the major product
(20)
. In vitro colonic metabolism 123 
was evaluated on tyrosol, hydroxytyrosol, hydroxytyrosol acetate and oleuropein showing an 124 
increase in phenolic acids, stability of hydroxytyrosol and tyrosol and degradation of 125 
hydroxytyrosol acetate and oleuropein mainly to hydroxytyrosol
(34)
. In order to evaluate OO 126 
phenolic metabolites produced from colonic fermentation, faecal samples were analysed before 127 
and after mid-term consumption of phenol-rich OO
(34)
. A significant increase in hydroxytyrosol 128 
concentration (p < 0.05) was observed after phenol-rich OO intake. Although absorption of OO 129 
phenolic compounds mainly occurr in the small intestine a small proportion of hydroxytyrosol 130 
and its derivatives still pass into the large intestine
(23)
. This highlights the need to study the 131 
impact of OO phenolics in the colon, either with gut microbiota interaction or local activity due 132 
to its antioxidant and anti-inflammatory properties.  133 
 134 
When assessing the chemical and in vitro biological antioxidant activities of these compounds, it 135 
is the glucuronides conjugates of hydroxytyrosol and tyrosol that must be assessed. These were 136 
tested in the range 0.01–10 μM against the radical 1,1-diphenyl-2-picrylhydrazyl (DPPH). None 137 
of the glucuronides displayed significant antioxidant activities at the concentrations tested, 138 
whereas the parent aglycones did display antioxidant activity at these concentrations
(35)
. This 139 
conflicts with the results of others
(36)
 with differences attributed to the fact that in one study 140 
reference standard material
(35)
 was used and in the other the glucuronide conjugates were 141 
extracted from urine samples
(36)
, and likely contained inpurities that had antioxidant activity. 142 
Hydroxytyrosol metabolites might act as "sinks" of hydroxytyrosol that could be locally released 143 
in the cells after enzymatic hydrolysis
(37)
, therby explaining the proposed hydroxytyrosol 144 
biological effects observed in vivo. Moreover, in situ deconjugation of hydroxytyrosol 145 
metabolites (into their free form) in red blood cells was observed in rats after oral administration 146 
of an OO phenolic extract obtained from olive cake (1.5 g/kg body weight, equivalent to 34.4 mg 147 
of hydroxytyrosol and derivatives), highlighting a potential protective mechanism against cell 148 
oxidative damage
(38)
.  149 
 150 
Although there are a number of biological effects for OO phenolic compounds, most cannot be 151 
achieved via normal dietary exposure to OO. This has led to development of enriched products 152 
with natural OO phenolic compounds. OO by-products such as olive mill wastewater
(39)
 and 153 
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olive pomace
(40, 41)
 are potential sources of natural bioactives which could be used to supplement 154 
OO. The development of new OO products such as pomace OO or refined olive oil (ROO) 155 
enriched in natural bioactives opens new perspectives in the field. 156 
 157 
2. Olive oil and inflammation  158 
Inflammation involves a complex cascade of events partly related with the production of an 159 
excess of free radicals due to internal or environmental stress
(42)
. The inflammation process 160 
triggers signaling molecules such as nuclear factor-kappa-B (NF-kB), which up-regulates the 161 
production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α)(43) inducible 162 
NO synthase (iNOS), cyclooxygenase-2 (COX-2), and interleukin-1beta (IL-1β)(42).  163 
A number of phenolic compounds present in OO have anti- inflammatory properties, including 164 
oleocanthal, a secoiridoid (dose-dependent inhibition of COX-1 and COX-2 activities, similar to 165 
the anti-inflammatory drug ibuprofen
(44)
). However, to achieve comparable effect to the 166 
recommended daily dose of ibuprofen, 500 g of EVOO would need to be consumed
(45, 46)
 making 167 
the dose/effect relationship outwith any (acute) inflammatory benefits due to typical OO 168 
consumption. 169 
 170 
Chronic inflammation 171 
Rheumatoid arthritis (RA) is a major inflammatory, autoimmune, disease characterized by 172 
chronic joint inflammation
(47, 48)
. Hydroxytyrosol has been studied for its anti-inflammatory 173 
effects in a RA animal model. We reported that it provided beneficial effects in the evolution of 174 
the disease
(49)
, with 0.5 and 5 mg/kg doses in rats, after gavage administration, using ROO as 175 
vehicle (human-equivalent of 4.9 and 49 mg/day, respectively, for a 60 kg adult), Figure 1. 176 
Significant effects, on paw edema reduction, were observed for a human-equivalent dose of       177 
49 mg/day, a dose 10 times higher than the approved European Food Safety Authority (EFSA) 178 
dose for phenolic compounds in relation to protection of lipid oxidation
(50)
. The same 179 
hydroxytyrosol dose was effective on colitis, another chronic inflammatory disease
(51)
. This dose 180 
would only be achievable through nutraceutical supplementation of OO with hydroxytyrosol, and 181 
the use of this functional food on a daily basis.   182 
To further evaluate the anti-inflammatory mechanisms involved with hydroxytyrosol, we studied 183 
COX-2 and iNOS expression
(49)
. The treatment at 5 mg/kg dose significantly decreased 184 
histological damage, COX-2 and iNOS expression (p<0.001 vs. positive control), markedly 185 
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reduced the degree of bone resorption, soft tissue swelling and osteophyte formation, improving 186 
articular function in treated animals. Moreover at the same dose there was a significant decrease 187 
(p<0.005 vs. positive control and ROO) in TNF-α serum levels. These results are in line with 188 
others that reported benefits on RA, in animal models, after oral administration of an EVOO 189 
extract
(52)
, intraperitoneal administration of oleuropein aglycone
(53)
 or polyphenol supplemented 190 
VOOs diets
(54)
. The reports highlight effects on RA of OO phenolic compounds either 191 
administered as isolated compounds or as an extract. However, doses comparison between 192 
animal studies have to to take in consideration not only differences in species (rats vs. mice) but 193 
also routes of administration. Compared to intraperitoneal administration, an oral dose has an 194 
extra pass through the liver with consequent metabolism through the first-pass effect.  195 
 196 
Acute inflammation 197 
Acute inflammation has been commonly induced using carrageenan in animals in order to 198 
evaluate the effects of non steroid anti-inflammatory drugs (NSAIDs)
(55)
. We studied the effect 199 
of hydroxytyrosol-supplemented OO on acute inflammation, induced by carrageenan in rats, at 200 
0.5 and 5 mg/kg
(49)
 dose, after gavage administration which occurred 30 min before the challenge 201 
with carrageenan. Both doses significantly reduced paw edema (p<0.001 vs. positive control) 202 
with the lowest effective dose being achievable through OO daily intake. Previous studies in 203 
rats
(56)
 also showed inhibition of carrageenan - acute inflammation of an aqueous hydroxytyrosol 204 
formulation (HT-20, 22% hydroxytyrosol), and significant effects were obtained at a 22 mg/kg 205 
hydroxytyrosol dose. Differences in dose effect might be related to the administration vehicle 206 
with ROO or OO being better vehicles than water.  207 
 208 
3. Cardioprotection of olive oil 209 
Most of the interventional studies focusing on the benefit of VOO intake on cardiovascular 210 
disease have investigated the effect of phenolic compounds on the prevention of oxidation of 211 
low-density (LDL) and high-density (HDL) lipoproteins
(57-64)
, two risk markers of cardiovascular 212 
disease. A number of trials have also focused on cardioprotection against inflammation
(65)
 213 
mainly on antioxidant activity and inflammatory mediators. 214 
 215 
 216 
 217 
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 218 
Impact of olive oil constituents on lipoproteins and atherosclerosis 219 
 220 
Fat content 221 
LDL particles carry about two-thirds of plasma cholesterol and can infiltrate the arterial wall 222 
attracting macrophages, smooth muscle cells, and endothelial cells
(66)
 thus driving atherosclerosis.  223 
LDL particle size is influenced by type and amount of dietary fat consumed
(67)
: Low-fat diets 224 
lead to a decrease in the size of LDL particles compared to high-fat diets
(68)
. The type of fat 225 
ingested is also important: LDL particles are larger with high-monounsaturated fatty acid diets 226 
(such as those based on OO), compared to diets with a high polyunsaturated fatty acids intake, 227 
where LDL particles are smaller
(69)
. LDL particle size is especially relevant, since small size 228 
particle are more prone to oxidation and can better enter into the arterial wall when compared 229 
with larger LDL particles
(70)
. Conversely, HDL particles are antiatherogenic, as their primarily 230 
role is to deliver cholesterol to the liver to be metabolized and excreted or reused. HDL may also 231 
be able to dislodge cholesterol molecules from atheromas in arterial walls
(66)
. It has been 232 
reported in patients with peripheral vascular disease
(71, 72)
, that LDL particles are less susceptible 233 
to oxidation when the diet is enriched in VOO monounsaturated fatty acids, compared to the 234 
polyunsaturated fatty acids of sunflower oil enriched diets. Moreover when compared to 235 
saturated fatty acids intake, OO oleic acid reduces the level of LDL-cholesterol
(63, 64)
. 236 
The health benefits associated with monounsaturated fat content in OO were recognised by the 237 
United States Food and Drug Administration (FDA) in 2004, highligthing “the benefits on the 238 
risk of coronary heart disease of eating about two tablespoons (23 g) of OO daily”(73). Health 239 
benefits were related with a decrease of total and LDL cholesterol in serum
(73)
, diet improvement 240 
of endothelial dysfunction
(74)
, coagulation activity
(75) 
and reduced LDL susceptibility to 241 
oxidation
(72)
.  242 
 243 
Phenolic content 244 
Antioxidants that can prevent lipid peroxidation, such as phenolic compounds, could play an 245 
important role in preventing oxidative modification of LDL
(4), 
with the oxidative process an 246 
initiating factor for atherosclerotic plaques
(76)
. Once monocytes differentiate in macrophages on 247 
the endothelium they scavenge oxidized LDL (ox-LDL), then becoming foam cells, leading to 248 
plaque formation
(5)
. 249 
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The Effect of Olive Oil on Oxidative Damage in European Populations (EUROLIVE) study was 250 
a cross-over fat replacement intervention
(58)
, using OOs with different phenolic content in 251 
healthy male volunteers. Its findings led to the current EFSA recommendation (Opinion of the 252 
Scientific Committee/Scientific Panel, EFSA Journal
(50, 77, 78)
). A linear increase in HDL-253 
cholesterol levels after 3 weeks was observed after low-, medium-, and high-polyphenol OO 254 
consumption: mean change from preintervention, 0.02 mmol/L (95% CI, 0.00 to 0.05 mmol/L), 255 
0.03 mmol/L (95% CI, 0.00 to 0.05 mmol/L) , and 0.04 mmol/L (95% CI, 0.02 to 0.06 mmol/L), 256 
respectively. Total cholesterol:HDL cholesterol ratio decreased linearly with the phenolic 257 
content of the OO. Triglyceride levels decreased by an average of 0.05 mmol/L for all OOs
(58)
. 258 
Mean changes from preintervention for ox-LDL levels were 1.21 U/L (95% CI, -0.8 to 3.6 U/L), 259 
-1.48 U/L(95% CI, -3.6 to 0.6 U/L) and -3.21 U/L (95% CI, -5.1 to -0.8 U/L) for the low-, 260 
medium-, and high-polyphenol OO, respectively, showing a dose-dependent relation with VOO 261 
phenolic content
(58)
. The EFSA confirmed a cause effect relationship between consumption of 262 
OO phenolics (standardized by the content of hydroxytyrosol and its derivatives) and protection 263 
of LDL cholesterol particles against oxidative damage. To support the EFSA health claim, 5 mg 264 
of hydroxytyrosol and its derivatives should be consumed daily in 20 g OO
(50)
, but 265 
concentrations in some OOs may be too low to achieve this target in the context of a balanced 266 
diet. Moreover, the EFSA Panel commented study design limitations as most human 267 
interventions with OO have been conducted in more homogeneous male populations
(77) 
and not 268 
in general population.  269 
 270 
The contribution of OO phenolics toward cardiovascular health benefits has been challenged 271 
with inconsistent results reported for ex vivo resistance of LDL to oxidation
(79, 80)
. Seven human 272 
intervention studies with OO were compared for impact of phenolics on ox-LDL, with no effect 273 
seen in five of them
(79)
, possibly explained by artifacts generated during LDL isolation.  274 
 275 
Since the approval of the EFSA claim, both terminology and analytical methodology supporting 276 
the dose calculation of hydroxytyrosol and derivatives have been appraised. Mastralexi et al.
(81)
 277 
commented on the weaknesses of the claim terminology namely the term “olive oil polyphenols” 278 
is not entirely clear and accurate as “olive oil” is a generic term for the type of oil, and the basic 279 
structure of OO phenolic compounds do not coincide with a “polyphenolic” structure; 280 
accordingly “virgin olive oil bioactive phenols” is a more appropriate term. Others also 281 
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commented about the lack of robust and reliable methods for quantifying phenolic compounds in 282 
OO. A simple and robust method for routine analysis of hydroxytyrosol and tyrosol was 283 
proposed
(81, 82) 
based on hydrolysis of the polar fraction of OO. This was followed by 284 
development and validation of a 
1
H NMR method enabling direct measurement of tyrosol and 285 
hydroxytyrosol derivatives, as well as oleocanthal and oleacein in OO, overcoming analytical 286 
issues such as chromatographic peak broadening
(19)
. 287 
 288 
Cardioprotective mechanisms of oleic acid 289 
OO intake has been related with a decrease on blood pressure with oleic acid regarded as being a 290 
major contributor to this effect, as evidenced in animal models
(83)
. Chronic oral administration of 291 
VOO (rich in oleic acid), triolein (a triacylglyceride with three oleic acid moieties) or oleic acid 292 
over 14 days significantly reduced systolic blood pressure in rats (-26 ± 4 for VOO and -21 ± 3 293 
mm Hg for triolein, p<0.001, and -17 ± 1.9 mm Hg for oleic acid p<0.05) when compared to the 294 
control group that received water. Similarly acute (2 h) treatments with either VOO or triolein 295 
also significantly reduced systolic blood pressure when compared to the control group                        296 
(-20 ± 0 mm Hg, p < 0.001, and -14 ± 2 mm Hg, respectively, p < 0.05) with oleic acid again 297 
significantly reducing systolic blood pressure (-13.0 ± 0.3 mm Hg; p < 0.001). In contrast, 298 
chronic treatment with the trans-monounsaturated fatty acid elaidic (18:1n-9) or the saturated 299 
fatty acid stearic acid (18:0) did not significantly affect blood pressure. Results show that 300 
saturation and cis/trans double bond arrangement are implicated with the cardioprotective effect 301 
of the long chain fatty acid in this animal model at high dose levels
(83)
. Similar significant results 302 
were obtained after VOO and oleic acid intake in an animal model of hypertension using 303 
spontaneously hypertensive rats
(83)
.  304 
The molecular mechanisms were evaluated by measuring signaling proteins involved in the 305 
control of blood pressure in the aorta. OO intake increases oleic acid levels in membranes, which 306 
regulate membrane lipid structure and impact on G protein-mediated signaling, causing a 307 
reduction in blood pressure
(84)
. Unlike its analogues elaidic and stearic acid, oleic acid, due to its 308 
cis-18:1n-9 structure, regulates cellular membrane lipid structure and the α2 receptor system 309 
involved in the control of blood pressure (α2A/D - adrenoreceptor/G protein/adenylyl cyclase-310 
cAMP/PKA) as demonstrated in vitro
(84)
 and in vivo
(83)
. Oleic acid can also contribute to heart 311 
health via intramyocardial triglyceride turnover
(85)
, which is reduced in pressure-overloaded 312 
failing hearts. In this situation oleate (derivative of oleic acid) upregulated triglyceride dynamics 313 
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when compared to palmitate (derivative of palmitic acid and major saturated fatty acid of palm 314 
oil). This result underscores the importance of the intracellular lipid storage type on nuclear 315 
receptor signaling and contractility
(85)
 in diseased hearts. 316 
An important driver of vasorelaxation is nitric oxide, a free radical which readily reacts with fats 317 
and proteins. Nitro-fatty acids are mediators of cardiovascular signaling actions
(86)
 as these 318 
compounds relax blood vessels, attenuate platelet activation, and reduce inflammation
(87, 88)
.  319 
Both oleic acid and linoleic acid are unsaturated fatty acids that after reaction with nitrite may 320 
form nitro-fatty acids. Nitro-oleic acid mediated antihypertensive signaling actions were shown 321 
in a mouse model
(89)
. The mechanism was attributed to the inhibition of soluble epoxide 322 
hydrolase by nitro-fatty acids, thus lowering blood pressure in an angiotensin II-induced 323 
hypertension
(89)
. It is however unclear how the extent of nitrite in the human diet may contribute 324 
to nitration of dietary fat, and the physiological relevance of this finding.  325 
 326 
Role of phenolic compounds on endothelium protection  327 
Oxidative stress and reactive oxygen species (ROS) have been implicated in endothelial damage, 328 
progression to atherosclerosis, injury in sustained myocardial infarction and ischemia 329 
reperfusion
(76, 90-92)
. Monocytes and macrophages are critical cells that are involved in 330 
atherosclerosis. These cells produce proinflammatory cytokines, such as IL-1β, TNF-α and         331 
C-reactive protein (CRP), which induce the expression of adhesion molecules like intercellular 332 
adhesion molecule-1 (ICAM-1), vascular-cell adhesion molecule-1 (VCAM-1), and E-selectin
(93)
.  333 
Meanwhile, oxidative stress through ROS production promotes the expression of the adhesion 334 
molecules on the endothelium
(94)
.  335 
Expression of adhesion molecules attracts circulating monocytes inducing their adherence to the 336 
endothelium. OO phenolic compounds have been shown to act on endothelium protection as 337 
evidenced in in vitro assays with typical OO phenolic compounds and less on in vivo circulating 338 
metabolites. OO phenolic extract, oleuropein aglycone or homovanillic alcohol (metabolite of 339 
hydroxytyrosol) had inhibitory effects on VCAM-1, ICAM-1 and E-selectin surface expression 340 
in human umbilical vascular endothelial cells, using TNF-α as pro-inflammatory stimulus(95).  341 
 342 
Endothelium dysfunction refers to an impairment of endothelium-dependent vasorelaxation 343 
caused by a loss of NO bioactivity in the vessel wall. In animal models with rats oral 344 
hydroxytyrosol administration was tested on NO production and platetet function
(96)
. Results 345 
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showed that hydroxytyrosol administration (100 mg/kg/day) increased vascular NO production 346 
by up to 34.2% (p < 0.01) and inhibited platelet aggregation for 50% inhibitory dose of          347 
48.25 mg/day for hydroxytyrosol (p<0.01) when compared to control group (treated with 348 
isotonic saline solution). Animal dose translation to humans allowed us to conclude that the 349 
effective hydroxytyrosol doses tested would be above the expected intake through OO daily. The 350 
reported benefits would only be achievable through nutraceutical supplementation.  351 
 352 
Endothelium repair: matrix metalloproteinases and olive oil 353 
Matrix metalloproteinases (MMPs) play a role in endothelium repair. Macrophages resident in 354 
human and experimental atherosclerosis co-localize with and release active MMPs including the 355 
gelatinase MMP-9, which is specialized in the digestion of basement membrane collagens and 356 
elastin, and is implicated in atherogenesis, unstable coronary syndromes, and in aortic 357 
aneurysms
(97)
. Accumulating evidence points to the MMPs as major molecular mediators of 358 
arterial diseases
(97)
. Collagens, types 1 and 3, are the main proteins in arterial walls being also 359 
present in the thickened intima of atherosclerotic lesions
(98, 99)
. Fragments of collagens found in 360 
urine are present as a result of proteolytic activity in arterial walls and other vascular structures. 361 
Collagen type 1 or 3 fragments were up-regulated in urine in coronary artery disease (CAD) 362 
patients
(100)
. Increase in collagen degradation is related with an increase on collagenases 363 
circulation, such as MMP-9, as shown in patients with CAD
(101)
.  364 
In an in vitro study hydroxytyrosol (1-10 μM) reduced MMP-9 (IC50 = 10 μmol/L, p< 0.05) and 365 
COX-2 induction in activated human monocytes, with phorbol myristate acetate (PMA)
(102)
. 366 
These effects were mediated by inhibition of transcription factor NF-κB and protein kinase C 367 
(PKC) α and PKCβ1 activation(102). Results are in line with previous in vitro reports that showed 368 
inhibition of MMP-9 on endothelial cells by OO phenolics namely hydroxytyrosol in PMA 369 
induced cells
(103)
, and oleuropein aglycone in TNF-α induced cells by acting on NF-κB(94). No 370 
hydroxytyrosol activity on MMP-9 was found in TNF-α induced cells(94). 371 
The discriminatory polypetides that increase in CAD includes collagen type 1 and 3 fragments 372 
with a C-terminal GxPGP motif
(104)
. Increase on these polypeptides would come from a protease 373 
decrease activity possibly related with chemical change of the substrate (e.g.: oxidative damage) 374 
thus inhibiting it acting at a specific site, or a decrease in circulating levels by lack of enzyme 375 
activation. MMP-2 is secreted in an inactive form (pro MMP-2) and several factors can promote 376 
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its activation such as plasmin
(105) 
and thrombin
(106)
. Other mechanisms that involve proteinases or 377 
oxidative stress can also activate MMP-2
(107)
. Therefore antioxidants, as phenolic compounds, 378 
might have a role on MMP-2 activation and published data indicate phenolic compounds from 379 
red wine
(108)
 and green tea
(109)
 as acting on prevention of thrombin-induced activation of MMP-2 380 
in vascular smooth cells. 381 
 382 
We evaluated the impact of a 6-week OO supplementation in healthy adults on urinary proteomic 383 
biomarkers of CAD in a randomized, parallel, controlled, double-blind study
(110)
. This study was 384 
the first to describe the significant impact of daily OO supplementation on highly specific 385 
disease biomarkers for CAD. Analysis of urinary proteomic profiles at baseline and endpoint 386 
enabled the identification of 12 sequenced peptides that were significantly regulated toward 387 
healthy scoring. Eight of them included four collagen α-1(I) chain, one α-2 (1) chain, one α-2(V) 388 
chain, and one α-2(VI) chain fragments. Changes in circulating concentrations of collagenases 389 
may mediate these changes in the urinary fingerprint. Therefore with more data or in future 390 
intervention studies with OO it would be interesting to link urinary fragments to the proteases 391 
involved in their generation. This predictive analysis would enable looking at the peptide 392 
cleavage sites studying the MMPs up or downregulated with OO intervention. 393 
 394 
The majority of studies of dietary intake of proposed bioactive foods asses the activities of these 395 
foods based on the major risk factors of cardiovascular disease. However marker such as 396 
lipoprotein profile, blood pressure, endothelial function, inflammation and oxidative stress have 397 
no direct link to the disease itself but are merely associated with it. There is a great need for more 398 
biomarkers that appear as a direct result of the disease itself
(63, 67)
. 399 
 400 
 401 
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4. Proteomics biomarkers as a mechanistic approach to explain olive oil health effects   402 
The systems biology approach (encompassing genomics, transcriptomics, proteomics and 403 
metabolomics using urine, blood or saliva) could provide a greater understanding of disease 404 
development, treatment efficacy and evaluation of the influence of food bioactive          405 
compounds
(46, 111)
. There is a need for biomarkers of practical value for clinical intervention, 406 
allowing disease risk prediction and more importantly early diagnosis. Accuracy, reproducibility, 407 
availability, feasibility of implementation into the clinical settings, sensitivity and specificity are 408 
additional characteristics to be fulfilled, and panels of biomarkers are gaining acceptance instead 409 
of individual molecules
(112)
, as single biomarkers are often not available and lack the ability to 410 
adequately describe complex diseases
(113)
. Candidate biomarkers should be carefully validated in 411 
a wide and different cohort of samples from those used in the discovery phase as often 412 
overfitting of the biomarker model has occurred
(114) 
.  413 
The proteome, corresponding to a set of expressed proteins, informs the current “status” of an 414 
organism, constantly changing according to endogenous and exogenous factors
(113)
. Proteins are 415 
widely used in different clinical tests for both diagnosis and prognosis of diseases and to follow 416 
their evolutions
(98)
. They can be used to measure the extent of inflammation, calcification, and 417 
the development of plaques on the arteries. Understanding what causes plaque rupture is of great 418 
importance. As previously mentioned, MMPs could have a key role in this process
(115)
. The 419 
discovery of proteomic biomarkers may be useful in understanding the molecular mechanisms 420 
involved in the onset and progression of other vascular diseases
(116)
. Plasma, serum and urine are 421 
the most commonly used biological matrices in cardiovascular research, due to their perceived 422 
clinical relevance as a source of potential biomarkers
(98)
. However proteomic studies have also 423 
been carried out on vascular tissues (arteries), artery layers, cells looking at proteomes and 424 
secretomes, exosomes, lipoproteins, and metabolites
(98)
. Although sampling the tissue may seem 425 
an obvious method there are a number of difficulties, especially where the need for a biopsy 426 
would be required
(117)
. Recent advances in extraction processes and LC-MS/MS analysis has 427 
allowed the quantitative analysis of tissue samples in vascular research to be carried             428 
out
(118, 119)
. 429 
Urine, as a sample source is now recognized as the source of choice for proteomic biomarker 430 
investigations. It has a number of advantages such as being noninvasive and can be collected by 431 
untrained personnel. Urine is produced by renal filtration of the plasma and approximately 70% 432 
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of proteins in the normal human urinary proteome are of kidney origin, whereas the remaining  433 
30% are derived from plasma proteins
(120, 121)
. It has high stability due to absence of proteolytic 434 
agents and the low dynamic range of analyte concentration facilitates the detection and 435 
quantification of peptides
(113, 122)
.  436 
Using capillary electrophoresis coupled with mass spectrometry (CE-MS)
(123) 
 urinary biomarker 437 
classifiers for the diagnosis of diseases like chronic kidney disease
(124)
, acute kidney injury
(125)
, 438 
stroke
(126)
, and coronary artery diseases
(104)
, were already identified, allowing classification of 439 
case versus control groups with good accuracy
(127)
. 440 
Urinary peptides and protein fragments are the end products of proteolytic processes. The 441 
different pattern of urinary excretion of peptides when comparing controls and disease patients 442 
might indicate their role in the pathophysiology of disease. Therefore changes in the normal 443 
urine "fingerprint" (e.g.: presence of collagen fragments) can be used as biomarkers of disease. 444 
Besides collagens, common blood proteins (e.g., alpha-1-antitrypsin, hemoglobin, serum 445 
albumin, and fibrinogen), and uromodulin were also identified
(128) 
in urine which provides 446 
additional proof of the suitability of this sample source for proteomic biomarker studies out with 447 
the kidney and urinary tract. Collagens are the most abundant peptides sequenced so far in the 448 
CAD biomarker (66% of all peptides)
(104)
, with atherosclerosis associated with an increased 449 
synthesis of several extracellular matrix components, including collagen types 1 and 3, elastin, 450 
and several proteoglycans
(129)
. Changes in the circulating levels of collagenases may mediate 451 
these changes in peptides represented in the fingerprint, as reported in coronary 452 
atherosclerosis
(100)
, and chronic kidney disease
(128)
. 453 
The progress in urinary proteomics and the use of multiple biomarker classifiers opens the 454 
possibility of establishing new tools adapted to different clinical needs
(130)
, enabling direct 455 
monitoring of disease overcoming limitations of indirect measurements.  456 
 457 
Proteomic in vitro studies on olive oil phenolic compounds 458 
Proteomics has been applied in a number of studies of OO phenolic compounds on 459 
cardiovascular health using animal and in vitro studies. The in vitro effects of alperujo extract, an 460 
OO production waste product containing phenolic compounds present in olive fruits, were 461 
studied on platelet aggregation and changes in the platelet proteome
(131)
. Nine proteins were 462 
differentially regulated by the alperujo extract upon platelet aggregation underlying the anti-463 
16 
 
platelet effects of the extract. However, like a number of previously mentioned in vitro studies, 464 
the effective concentrations (40-500 mg/L) were far above the physiologically concentrations 465 
achievable by dietary intake.  466 
The effects of EVOOs, with low and high in phenolic content, were evaluated in the hepatic 467 
proteome in Apoe
-/- 
mice that spontaneously develop atherosclerosis
(132)
. For 10 weeks the mice 468 
were fed with
 
a high fat high cholesterol diet supplemented with 0.15% (w/w) cholesterol and 469 
either 20% (w/w) low phenolic EVOO or 20% (w/w) high phenolic EVOO versus a control 470 
group fed with 0.15% (w/w) cholesterol and 20% (w/w) palm oil. Within this work a range of 471 
hepatic antioxidant enzymes differentially regulated by OO
(132)
 were identified. The authors 472 
concluded that the up-regulation of a large array of antioxidant enzymes might explain anti-473 
atherogenic mechanisms of EVOOs
(132)
. Again the dose level was above what could be achieved 474 
through dietary intake and translation from an animal model to human has also to be considered. 475 
 476 
Urinary proteomics biomarkers, olive oil and cardiovascular disease 477 
Atherosclerosis is a process of chronic inflammation, characterized by the accumulation of 478 
lipids, cells, and fibrous elements in medium and large arteries
(98)
. The extent of           479 
inflammation, proteolysis, calcification, and neovascularization influences the development of 480 
advanced lesions (atheroma plaques) on the arteries
(98)
.  481 
Classical risk factors in atherosclerosis (hypertension, LDL-cholesterol, C-reactive protein, 482 
aging, smoking, male gender, among others) do not actually measure disease initiation or 483 
progression. As such, they cannot be used directly to identify individuals who have developed 484 
atherosclerosis and prevent a fatal event
(98, 133)
. Other, more recent markers that indicate changes 485 
in vascular structure can still only be detected once cardiovascular disease has progressed to an 486 
advanced stage where drug or surgical intervention is required
(134)
.  487 
The analysis of urine samples from diseased and healthy individuals has been used to establish a 488 
database of naturally occurring urinary peptides, making a basis for the definition and validation 489 
of biomarkers for diagnosis/prognosis/monitoring of a wide range of diseases using proteomic 490 
biomarker patterns
(128)
, such as CAD
(100)
, emphasizing that non-invasive proteomics analysis 491 
could become a valuable addition to assess cardiovascular disease alongside to other biomarkers 492 
which are indicators of cardiovascular risk.  493 
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The first time that urinary proteomics was applied to assess cardiovascular health improvements 494 
of OO consumption in humans, was in a randomized, parallel, controlled, double-blind study 495 
designed to evaluate the impact of a 6 week OO supplementation in healthy adults on urinary 496 
proteomic biomarkers of CAD
(110)
. The impact of the supplementation with OO was also studied 497 
on urinary proteomic biomarkers of chronic kidney disease (CKD), and diabetes. 498 
The increase or decrease in the concentration of the peptides in the biomarker determines the 499 
scoring value of each disease biomarker. The CAD proteomic biomarker developed for clinical 500 
diagnosis produces a CAD scoring system from 1 (CAD case) to -1 (healthy artery). A scoring of 501 
disease absence, presence and severity is provided, based on the concentration of a group (panel) 502 
of urinary peptides measured by CE-MS, allowing monitoring of progression and/or effect of 503 
treatment
(135, 136)
. In this study, self-reported healthy participants were randomly allocated to 504 
supplementation with a daily dose of OO either low or high in phenolic compounds. For 6 505 
weeks, they consumed a daily dose of 20 mL OO (not heated or cooked) as a supplement (no 506 
specific time during the day, single intake, equivalent to 6 mg of hydroxytyrosol and derivatives 507 
for the high phenolic OO), in line with the EFSA and FDA recommendations.The impact of 508 
supplementation with OO was evaluated on urinary proteomic biomarkers of CAD with 509 
biomarkers being measured at baseline and 3 and 6 weeks. Consumption of both OOs 510 
significantly improved the proteomic CAD score at endpoint compared with baseline, moving 511 
the CAD biomarker pattern in a healthy profile direction, Table 2. No differences were observed 512 
for CKD or diabetes proteomic biomarkers, Table 2. 513 
In a placebo-controlled intervention, Irbesartan (angiotensin II receptor antagonist used for the 514 
treatment of hypertension) taken at 300 mg per day over 2 years in hypertensive type 2 diabetes 515 
patients, using the CAD 238 biomarker panel, led to a 0.35 point reduction in the CAD score for 516 
the drug-controlled group
(104)
, which saw a significant reduction in incidents of CAD in this 517 
group. In the nutritional intervention
(110) 
the CAD score change in the intervention was 518 
significant for both OOs tested, using the same CAD 238 biomarker, leading to a similar degree 519 
of change as observed for irbersartan over a 6 week period. This evidence highlights the 520 
importance of the CAD biomarker as a tool for nutrition and health intervention studies. This 521 
type of urinary biomarker enabled the measurement of health effects induced by a change in diet 522 
that could not be detected by monitoring the conventional risk markers of CAD such as plasma 523 
triacylglycerols, oxidized LDL, and LDL cholesterol. The overall change in CAD score in a 524 
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short period of time is more likely due to OO major components, such as fatty acids. However 525 
the role of other OO minor components other than phenolic compounds should also be taken into 526 
account. Squalene, a polyunsaturated triterpene which makes up 60–75% of the unsaponifiable 527 
fraction of OO
(137)
, reduced atherosclerotic lesion size in male mice
(138)
 and further investigation 528 
is needed to clarify its role on cardiovascular disease.  529 
 530 
Our results emphasize further the potential role of nutrition in the prevention or delay of 531 
cardiovascular disease and offer new perspectives on OO applications. These results are highly 532 
translatable to guidelines for nutritional recommendations. The biomarkers were originally 533 
developed to detect early signs of diseases in clinical setting and to inform clinician as to the 534 
effectiveness of treatment. However, the technology also provides a sensitive tool for the 535 
assessment of potential bioactive foods in cardiovascular health, chronic kidney disease and 536 
diabetes, with a range of additional tests under development. Further testing of reportedly 537 
bioactive foods can now be carried out which will allow better nutritional health advice to be 538 
advanced and could also lead to better food labeling so that the public can make informed 539 
choices on their food purchases. 540 
 541 
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5. Exploring olive oil health benefits: perspectives 
Although strong evidence from heritability is related with cardiovascular disease many forms of 
heart disease are not genome associated
(139)
. The epigenome is a possible link between genetics 
and environment
(139)
 which includes impact of food components/diet. Omics techniques 
(genomics, transcriptomics, proteomics, epigenomics, metabolomics) have the potential, when 
integrated, to paint a comprehensive picture of the contribution of diet toward the modulation of 
disease risk
(141)
. Some trials have shown the impact of OO on down-regulation of 
atherosclerosis-related genes
(140, 141)
. The effect of Mediterranean Diet was studied on urinary 
metabolome
(142)
 and related to compounds of the metabolism of carbohydrates, creatine, 
creatinine, amino acids, lipids and microbial cometabolites. 
Phenolic compounds can interact with cellular signaling cascades regulating the activity of 
transcription factors with impact on gene expression. For instance, phenolic compounds have 
shown to affect the expression of microRNAs (miRNA)
(143)
. miRNAs are small, noncoding 
RNAs implicated in the regulation of gene expression that control both physiological and 
pathological processes, influenced by external factors as diet components
(144)
. Most of the studies 
reported in this field are in vitro and more in vivo studies are needed to clarify miRNA targets of 
dietary phenolic compounds
(144)
. 
Interactions between genes and the bioactive components present in OO studied by 
nutrigenomics may help to explain its health benefits
(145)
. In this sense, besides their antioxidant 
and anti-inflammatory capacities, OO phenolic compounds are able to modify gene expression 
coding in a protective mode for proteins participating in the cellular mechanisms involved in 
oxidative stress resistance, inflammation or lipid metabolism amongst others
(146)
. 
Glycation, a non-enzymatic reaction between reducing sugars and proteins, is a proteome wide 
phenomenon, mainly observed in diabetes due to hyperglycemia
(147)
, but also relevant to end 
organ damage, disease pathogenesis and aging
(148)
 and OO phenolic compounds have been 
reported as potent inhibitors of the formation of advanced glycation end products
(149)
. Our human 
intervention trial with OO low or high in phenolics did not find a significant impact on plasma 
fructosamine levels
(110)
. A key factor may be the duration of the study (6 weeks) not being 
sufficient to detect changes in protein modifications such as glycation, and may also be partly 
related to the quantity and quality of phenolic compounds, which exert differential antioxidant 
and antiglycative activities depending on        structure
(4, 150)
. Further studies should proceed in 
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order to clarify anti-glycation properties of OO phenolic compounds, given that glycation is a 
key driver for tissue damage and is present in all non-communicable disease scenarios. 
 
6. Conclusion  
Results outlined in this review provide evidence of health benefits related with OO intake. The 
reported studies may allow the implementation of primary prevention programs of 
cardiovascular disease, based on nutritional interventions, useful in non-regular OO consumers 
groups like the Northern European populations. Interventions in broad populations with highly 
specific disease biomarkers, as urinary proteomic biomarkers, will offer higher translational 
value, especially toward development and implementation of new nutritional  recommendations. 
Human intervention trials focusing on new outcomes related with proteomics and nutrigenomics 
are needed to better clarify pathways/mechanisms by which oleic acid, phenolic compounds or 
even other OO components act on cardiovascular disease risk factors and affect the proteome.  
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Table 1 – Main classes of phenolic compounds in virgin olive oil  
Phenolic acids Phenolic alcohols  Flavonoids 
 
  
 
Caffeic acid Hydroxytyrosol  Tyrosol Luteolin 
Lignans Secoiridoids   
 
  
 
 
(+) - Pinoresinol Oleuropein aglycone  
(3,4-DHPEA-EA) 
Ligstroside aglycone 
(p-HPEA-EA) 
Dialdehydic form of deacetoxy 
oleuropein (3,4-DHPEA-EDA) 
 
 
 
 
OH
OH
CH
CH
COOH
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Table 2 Changes in scores of CAD, CKD and diabetes proteomic biomarkers at baseline, middle (3-weeks) and  
end of intervention (6 weeks)
1
 
  Low phenolic 
olive oil (n = 
34) 
High phenolic 
olive oil (n = 
28) 
  Score Score 
CAD proteomic biomarker baseline -0.5 ± 0.2 -0.6 ± 0.4 
 3 weeks -0.7 ± 0.3 -0.7 ± 0.3 
 6 weeks -0.8 ± 0.3** -0.8 ± 0.3* 
CKD proteomic biomarker baseline -0.4 ± 0.2 -0.4 ± 0.3 
 3 weeks -0.4 ± 0.2 -0.4 ± 0.3 
 6 weeks -0.4 ± 0.2 -0.4 ± 0.2 
Diabetes proteomic biomarker baseline 1.3 ± 0.3 1.3 ± 0.3 
 3 weeks 1.3 ± 0.4 1.3 ± 0.3 
 6 weeks 1.4 ± 0.4 1.2 ± 0.3 
1
Values are means ± SDs; 95% CIs in parentheses. A repeated-measures ANOVA test was used with statistical significance at p < 0.05. ***Compared with 
corresponding baseline value: *p < 0.005, **p < 0.001. There were no significant differences in changes between groups. CAD, coronary artery disease; CKD, 
chronic kidney disease (adapted from Silva et al.
(104)
). 
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Figure 1 – Chronic inflammation model and impact on rats paw edema (ANOVA, * p < 0.001 vs. postive 
control – Rheumatoid Arthritis, + p < 0.01 vs. Refined Olive Oil; OHTYR = hydroxytyrosol) (adapted 
from Silva et al.
(49)
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